RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload

采用 G 蛋白肽有效负载设计的 RSV 纳米胶囊疫苗

基本信息

  • 批准号:
    7902985
  • 负责人:
  • 金额:
    $ 59.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the most important cause of severe lower respiratory tract illness in infants and the elderly. Currently, no safe and efficacious RSV vaccine exists. Advances in our understanding of immunity and disease pathogenesis associated with infection have shown that RSV G protein contains a CX3C chemokine motif that interacts with the CX3CR1 chemokine receptor, modifies the activities of CX3CL1, and affects aspects of immunity and disease pathogenesis. Antibodies directed to the CX3C motif inhibit G protein CX3C-CX3CR1 interaction and reduce disease pathogenesis. The long- term goal of our research is to develop a novel nanocapsule vaccine engineered to carry a RSV G protein polypeptide that we have previously shown to induce neutralizing and disease protective antibody. The nanocapsule technology is attractive for vaccine development as it targets professional antigen- presenting cells which we have shown to improve the immunogenicity of both T cell and antibody target epitopes. The proposal will take advantage of well-defined assays and a mouse model to: (1) Identify the optimal CX3C motif vaccine antigen sequence based on G polypeptide vaccination of mice and evaluation of G protein CX3C-CX3CR1 blocking antibody responses, (2) Construct nanocapsule vaccine candidates with the appropriate G polypeptide and demonstrate immunogenicity and protection in a mouse model, (3) Use optimized, efficacious nanocapsule vaccines to further understand the disease modifying effect of antibodies that block G protein CX3C-CX3CR1 interaction and disease pathogenesis, 4) Evaluate parameters of safety and duration of vaccine efficacy in the memory response to (G peptide nanocapsule vaccination and RSV challenge, and (5) Evaluate the safety and efficacy of G peptide nanocapsule vaccine in the context of pre-existing RSV immunity. The proposed research is innovative because it will identify regions in the RSV G protein that induce antibodies which neutralize infection and block RSV disease, incorporate the optimal polypeptide in an novel nanocapsule-based vaccine candidate that targets antigen-presenting cells, and will provide long-term protection against RSV strains. Respiratory syncytial virus is the most important cause of sever lower respiratory tract illness in infants and the elderly. Currently, no safe and efficacious RSV vaccine exists. The long-term goal of our research is to develop a novel nanocapsule vaccine engineered to carry a RSV G protein polypeptide that we have previously shown to induce neutralizing and disease protective antibody.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RALPH A TRIPP其他文献

RALPH A TRIPP的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RALPH A TRIPP', 18)}}的其他基金

RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload
采用 G 蛋白肽有效负载设计的 RSV 纳米胶囊疫苗
  • 批准号:
    8636392
  • 财政年份:
    2010
  • 资助金额:
    $ 59.31万
  • 项目类别:
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload
采用 G 蛋白肽有效负载设计的 RSV 纳米胶囊疫苗
  • 批准号:
    8450155
  • 财政年份:
    2010
  • 资助金额:
    $ 59.31万
  • 项目类别:
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload
采用 G 蛋白肽有效负载设计的 RSV 纳米胶囊疫苗
  • 批准号:
    8051743
  • 财政年份:
    2010
  • 资助金额:
    $ 59.31万
  • 项目类别:
RSV Nanocapsule Vaccine Engineered with a G Protein Peptide Payload
采用 G 蛋白肽有效负载设计的 RSV 纳米胶囊疫苗
  • 批准号:
    8247796
  • 财政年份:
    2010
  • 资助金额:
    $ 59.31万
  • 项目类别:
Immunobiology of Influenza Virus Infection: Approaches for an Emerging Zoonotic D
流感病毒感染的免疫生物学:新出现的人畜共患病 D 的方法
  • 批准号:
    7334084
  • 财政年份:
    2007
  • 资助金额:
    $ 59.31万
  • 项目类别:
Antibody inhibition of respiratory syncytial virus G protein activity
抗体抑制呼吸道合胞病毒G蛋白活性
  • 批准号:
    7339847
  • 财政年份:
    2007
  • 资助金额:
    $ 59.31万
  • 项目类别:
Antibody inhibition of respiratory syncytial virus G protein activity
抗体抑制呼吸道合胞病毒G蛋白活性
  • 批准号:
    7179193
  • 财政年份:
    2007
  • 资助金额:
    $ 59.31万
  • 项目类别:
Antibody inhibition of respiratory syncytial virus G protein activity
抗体抑制呼吸道合胞病毒G蛋白活性
  • 批准号:
    7744001
  • 财政年份:
    2007
  • 资助金额:
    $ 59.31万
  • 项目类别:
Antibody inhibition of respiratory syncytial virus G protein activity
抗体抑制呼吸道合胞病毒G蛋白活性
  • 批准号:
    7552034
  • 财政年份:
    2007
  • 资助金额:
    $ 59.31万
  • 项目类别:
MECHANISMS OF CYTOTOXIC T CELL SPECIFICTY TO ADENOVIRUS
腺病毒的细胞毒性 T 细胞特异性机制
  • 批准号:
    3030313
  • 财政年份:
    1992
  • 资助金额:
    $ 59.31万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59.31万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 59.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
    Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
    Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 59.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了